Free Trial
NASDAQ:GLUE

Monte Rosa Therapeutics Q3 2024 Earnings Report

Monte Rosa Therapeutics logo
$3.85 -0.29 (-7.00%)
Closing price 04:00 PM Eastern
Extended Trading
$3.83 -0.02 (-0.52%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Monte Rosa Therapeutics EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.45
Beat/Miss
Beat by +$0.16
One Year Ago EPS
N/A

Monte Rosa Therapeutics Revenue Results

Actual Revenue
$9.22 million
Expected Revenue
$4.54 million
Beat/Miss
Beat by +$4.68 million
YoY Revenue Growth
N/A

Monte Rosa Therapeutics Announcement Details

Quarter
Q3 2024
Time
N/A
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Monte Rosa Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025

Monte Rosa Therapeutics Earnings Headlines

Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
Monte Rosa Therapeutics: Exercise Extreme Caution
See More Monte Rosa Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Monte Rosa Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Monte Rosa Therapeutics and other key companies, straight to your email.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics (NASDAQ:GLUE), a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

View Monte Rosa Therapeutics Profile

More Earnings Resources from MarketBeat